Streamlining Vabysmo Prior Authorization for Gastroenterology Practices

Understanding Vabysmo Prior Authorization in a Gastroenterology Context

Vabysmo (faricimab) is an anti-VEGF and anti-Ang-2 therapeutic agent indicated for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME), conditions typically managed by ophthalmologists. While not a primary gastroenterology medication, a GI practice might encounter Vabysmo prior authorization requests when coordinating care for patients with complex medical histories or within integrated health systems managing all PAs centrally. This necessitates a robust system capable of handling diverse drug PAs.

General Prior Authorization Requirements for Vabysmo

Regardless of the prescribing specialty, Vabysmo prior authorization typically requires documentation of the specific ophthalmological diagnosis (e.g., nAMD, DME), evidence of medical necessity, and adherence to payer-specific step therapy protocols or treatment guidelines. Payers often review prior treatment history with other anti-VEGF agents and visual acuity assessments. Klivira's platform centralizes access to payer policies for various medications, including those outside a specialty's primary focus.

Key Documentation for Gastroenterology Prior Authorizations

• Diagnosis confirmation (endoscopic, imaging, histologic) and disease severity assessment (Mayo score for UC, CDAI for Crohn's).
• Prior conventional-therapy trial (e.g., 5-ASA for UC, immunomodulators for moderate-severe IBD) and prior biologic experience.
• TB and hepatitis screening pre-initiation for IBD biologics.
• Genotype, fibrosis stage, prior-treatment history, and drug-drug interaction review for Hepatitis C DAAs.
• Clinical question, prior imaging history, and conservative-evaluation workup for advanced imaging (MRCP, MR enterography).

Addressing Gastroenterology-Specific PA Challenges

Gastroenterology practices face unique PA complexities beyond specific drug requirements. The chronic nature of conditions like IBD necessitates periodic re-authorization for biologics, requiring continuous documentation of disease response. The variability in biosimilar substitution policies and the medical-vs-pharmacy benefit split for infused versus self-administered biologics further complicate workflows. Klivira integrates with EMRs to capture and track these critical data points, ensuring timely re-authorizations and correct benefit routing.

Mitigating Common Prior Authorization Denials in GI

• Failure to meet step therapy requirements for IBD biologics (e.g., conventional therapy or biosimilar trial).
• Inadequate documentation of disease severity (e.g., missing Mayo score, CDAI).
• Gaps in required pre-treatment screenings (e.g., TB, hepatitis for biologics).
• Insufficient documentation of fibrosis stage or drug-drug interaction review for Hep C DAAs.
• Lack of clinical correlation or prior workup for advanced imaging or capsule endoscopy requests.

Klivira's Solution for Gastroenterology Prior Authorization

Klivira's platform provides a comprehensive solution for gastroenterology practices, automating the submission and tracking of prior authorizations across various channels, including payer portals and X12 278 transactions. Our system incorporates ACG/AGA-guideline-aware logic for IBD biologic sequencing, automates treatment-status classification from EMR data, and supports complex workflows for Hep C DAAs and diagnostic procedures. This ensures compliance with payer rules and reduces administrative burden.